683 Capital Management, LLC Otonomy, Inc. Transaction History

683 Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $2.39 Million - $5.98 Million	-960,054 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $208,987 - $388,549	60,054 Added 6.67%	960,054 $6.21 Million
Q1 2020 May 15, 2020	SELL	$1.58 - $4.06 $316,000 - $811,999	-200,000 Reduced 18.18%	900,000 $1.77 Million
Q4 2018 Feb 14, 2019	BUY	$1.51 - $2.93 $453,000 - $879,000	300,000 Added 37.5%	1,100,000 $2.04 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $555,000 - $712,500	150,000 Added 23.08%	800,000 $3.08 Million
Q1 2018 May 15, 2018	BUY	$4.05 - $6.1 $405,000 - $610,000	100,000 Added 18.18%	650,000 $2.73 Million
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $1.54 Million - $3.05 Million	550,000	550,000 $3.05 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.